Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer

Darian Andreas; Jeffrey J Tosoian; Patricia Landis; Sacha Wolf; Stephanie Glavaris; Tamara L Lotan; Edward M Schaeffer; Lori J Sokoll; Ashley E Ross

doi:10.1016/j.eucr.2016.04.012

Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer

Urol Case Rep. 2016 May 26:7:64-6. doi: 10.1016/j.eucr.2016.04.012. eCollection 2016 Jul.

Authors

Darian Andreas¹, Jeffrey J Tosoian¹, Patricia Landis¹, Sacha Wolf¹, Stephanie Glavaris¹, Tamara L Lotan², Edward M Schaeffer³, Lori J Sokoll⁴, Ashley E Ross¹

Affiliations

¹ The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
² Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
³ Department of Urology, Northwestern University, Chicago, IL 60611, USA.
⁴ The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Abstract

The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy of a gentleman undergoing active surveillance leading to reclassification of his disease as high risk prostate cancer.

Keywords: Active surveillance; Biomarkers; Prostate biopsy; Prostate cancer.

Publication types

Case Reports

Grants and funding

P30 CA060553/CA/NCI NIH HHS/United States